Biotech Adocia has named two senior members of its team that will be based at its new subsidiary in the US.
Simon Bruce (top pictured) has been named as chief medical officer, while Stephen Daly has been appointed as US commercial lead and will be in charge of the business development in the US in addition to US investor relations.
Bruce has over 15 years of experience in drug development and registrational drug trials. He joins from Halozyme Pharmaceuticals, where he held the position of executive medical director and worked on the ultra-rapid insulin programme.
Bruce has also held position at Amylin Pharmaceuticals, where he was in charge of Bydureon’s phase III studies and safety analysis, a once weekly GLP-1 injectable formulation.
Daly has 24 years of experience in commercialisation and business development for pharma and biotech products across multiple therapeutic categories. He most recently served as VP of commercial at Halozyme, also on the ultra-rapid insulin programme.
Daly’s experience in the diabetes field also includes several years at Amylin, where he worked on the marketing and brand leadership for Byetta and Symlin.
Olivier Soula, R&D director and deputy general manager at Adocia, commented: “Their knowledge and experience in drug development, especially in the diabetes field, are unique from both medical and commercial perspective.
“They are indisputable assets to accelerate the development and commercialisation of our projects and to optimise our collaborative research in partnerships.”